Get started
Author

K. Possinger

Observed names: K Possinger, K. POSSINGER, K., Possinger, K.W. Possinger, Possinger K., Possinger, K.
Observed institutions: Goethe University Frankfurt, University of Pittsburgh, Cal Poly Humboldt, Universität Ulm, University Medical Center Freiburg, Charing Cross Hospital, Helmholtz Munich, LMU Klinikum, Medizinische Hochschule Hannover, Humboldt-Universität zu Berlin, Asklepios Klinik Altona, Westpfalz Klinikum, Universitätsklinikum Tübingen, Graz University Hospital, German Cancer Society, University Hospital Münster, University Medical Center Hamburg-Eppendorf, Central European Cooperative Oncology Group, Francis Hospital, Klinikum Leverkusen, University Hospital Ulm, St. Bonifatius Hospital, Stiftung Charité, Pathologisches Institut, Freie Universität Berlin, Friedrich Schiller University Jena, Charité – Universitätsmedizin Berlin, University of Tübingen, Ludwig-Maximilians-Universität München
OpenAlex ID: A5110906434
Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors.
1996 · A S Lübbe, C Bergemann, et al. · PubMed · 654
Advanced breast cancer: a phase II trial with gemcitabine.
1995 · J Carmichael, K Possinger, et al. · Journal of Clinical Oncology · 338
Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
1998 · G Cocconi, D Cunningham, et al. · Journal of Clinical Oncology · 215
Mucormycoses
2001 · J. Eucker, O. Sezer, et al. · Mycoses · 190
PPARγ Ligands and ATRA Inhibit the Invasion of Human Breast Cancer Cells in vitro
2003 · H. Liu, C. Zang, et al. · Breast Cancer Research and Treatment · 170
Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer
2000 · V. Heinemann, H. Wilke, et al. · Annals of Oncology · 169
Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma
2000 · O. Sezer, K. Niemöller, et al. · Annals of Hematology · 147
Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer
1999 · K Possinger, M Kaufmann, et al. · Anti-Cancer Drugs · 131
Second consensus on medical treatment of metastatic breast cancer
2006 · S. Beslija, J. Bonneterre, et al. · Annals of Oncology · 92
Novel Therapeutic Approach: Ligands for PPARγ and Retinoid Receptors Induce Apoptosis in bcl-2-positive Human Breast Cancer Cells
2002 · E. Elstner, E.A. Williamson, et al. · Breast Cancer Research and Treatment · 85
Tumor type M2 pyruvate kinase expression in advanced breast cancer.
2000 · D Lüftner, J Mesterharm, et al. · PubMed · 84
Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study.
1990 · K Höffken, W Jonat, et al. · Journal of Clinical Oncology · 83
High-Dose Chemotherapy With Autologous Hematopoietic Stem-Cell Support Compared With Standard-Dose Chemotherapy in Breast Cancer Patients With 10 or More Positive Lymph Nodes: First Results of a Randomized Trial
2004 · A.R. Zander, N. Kröger, et al. · Journal of Clinical Oncology · 80
Endocrine treatment options for advanced breast cancer – the role of fulvestrant
2004 · J.F.R. Robertson, S.E. Come, et al. · European Journal of Cancer · 79
Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer
2012 · C F Jehn, L Böning, et al. · British Journal of Cancer · 78
PDF
Expression of high-mobility-group-protein HMGI-C mRNA in the peripheral blood is an independent poor prognostic indicator for survival in metastatic breast cancer
2003 · C Langelotz, P Schmid, et al. · British Journal of Cancer · 78
PDF
CA27.29
2001 · M Gion, R Mione, et al. · European Journal of Cancer · 72
Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas
2000 · E Späth-Schwalbe, I Genvresse, et al. · Anti-Cancer Drugs · 70
Influence of age, performance status, cancer activity, and IL-6 on anxiety and depression in patients with metastatic breast cancer
2012 · C. F. Jehn, B. Flath, et al. · Breast Cancer Research and Treatment · 65
Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma
2013 · A.H. Meyer, A. Stroux, et al. · Annals of Oncology · 59
Orbital metastases in breast cancer: report of two cases and review of the literature
2004 · A. Dieing, C.-O. Schulz, et al. · Journal of Cancer Research and Clinical Oncology · 59
The comparability of quality of life scores
2002 · S Kuenstner, C Langelotz, et al. · European Journal of Cancer · 58
A comparison of international breast cancer guidelines – Do the national guidelines differ in treatment recommendations?
2011 · R. Wolters, A.C. Regierer, et al. · European Journal of Cancer · 56
Detection of Microsatellite Alterations in the DNA Isolated from Tumor Cells and from Plasma DNA of Patients with Lung Cancer
2000 · N. BRUHN, T. BEINERT, et al. · Annals of the New York Academy of Sciences · 56
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines
2008 · P. Schmid, D. Kühnhardt, et al. · Annals of Oncology · 55
Works count: 328
Citation count: 5,012
H-index: 36
I10-index: 83
Year
Topic
Type